Australia's Immuron rises as full-year loss shrinks, revenue grows
** Shares of Immuron IMC.AX rise as much as 4.4% to A$0.072, their highest level since August 20 ** The biopharmaceutical co's annual loss after income tax expense attributable shrinks to A$5.3 million ($3.38 million) from a loss of A$6.9 million last year ** Reports FY revenue of A$7.3 million from A$4.9 million a year ago ** Stock down 8.9% YTD, including the session's moves ($1 = 1.5389 Australian dollars) (Reporting by Anjali Singh in Bengaluru) ((anjali.singh2@thomsonreuters.com;))
Recent news on Immuron
See all newsBrief: Immuron Engages LifeSci Capital as its Exclusive Financial Advisor to Explore Strategic Initiatives
Australia's Immuron hits near 1.5-month high on distribution deal in US
Brief: Immuron Executes Exclusive Distribution Agreement For Proibs In The United States
Brief: Immuron Reports FY26 Preliminary Results
Brief: Immuron Posts FY Revenue From Ordinary Activities Of A$7.71 Million